X4 Pharmaceuticals (XFOR) Intangibles (2019 - 2025)
X4 Pharmaceuticals (XFOR) posted Intangibles of $9.2 million for Q4 2025, down 1.6% on a QoQ basis from $9.4 million in Q3 2025, and down 7.5% year-over-year from $10.0 million in Q4 2024.
X4 Pharmaceuticals (XFOR) Intangibles (2019 - 2025) Analysis & Trends
X4 Pharmaceuticals' Intangibles history runs 3 years deep, the most recent figure standing at $9.2 million for Q4 2025.
- Quarterly Intangibles fell 7.5% year-over-year to $9.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.2 million (down 7.5% YoY) and the FY2025 annual result came in at $9.2 million, down 7.5% from the prior year.
- Intangibles was $9.2 million for Q4 2025 at X4 Pharmaceuticals, down from $9.4 million in the prior quarter.
- Across five years, Intangibles topped out at $10.4 million in Q2 2024 and bottomed at $9.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 16.97 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 11,640.44 |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 30.30 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 61.68 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 418.50 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 1.29 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 266.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 55.80 Mn |
| 10 | X4 Pharmaceuticals | 167.90 Mn | -49.15 Mn | 2.20 Mn | 9.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.25 Mn |
| Sep 30, 2025 | 9.40 Mn |
| Jun 30, 2025 | 9.60 Mn |
| Mar 31, 2025 | 9.81 Mn |
| Dec 31, 2024 | 10.00 Mn |
| Sep 30, 2024 | 10.19 Mn |
| Jun 30, 2024 | 10.40 Mn |
| Jun 30, 2019 | 4.90 Mn |
| Mar 31, 2019 | 4.90 Mn |